Skip to main content
TYRATyra Biosciences, Inc.Sell5.3·$19.57
SellModerate Confidence
Investment thesis

Tyra Biosciences is a cash-burning clinical-stage biotechnology company focused on oral dabogratinib with 57% analyst upside and institutional accumulation, but a quality score of 1.2 out of 10, a put/call ratio of 88, and an implied volatility of 207% reflect extreme uncertainty around the binary clinical outcome.

Thesis pillars

  • Extreme Options Market Hedging↑Improving
  • Oral Dabogratinib Pipeline Concentration↑Improving
  • Institutional Accumulation Signal→Stable
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Mar 2, 2026· older than 90 days

Full reasoning →

Open full analysis

Tyra Biosciences, Inc. (TYRA) Stock Analysis

Falling Knife setup · Inst Constrain edge

SellShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $19.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 3.26; Below-average business quality.

Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or commercial revenue. The lead program, oral dabogratinib, is advancing through three concurrent Phase 2 trials in LG-UTUC, IR NMIBC, and achondroplasia in... Read more

$19.57+111.0% A.UpsideScore 5.3/10#99 of 240 Biotechnology
QualityF-score4 / 9FCF yield-4.95%
Stop $18.69Analyst target $41.29(−13% haircut)A.R:R 9.2:1
Analyst consensus$47.45+142.5%11 analysts with price targets
$41.29Analyst target
$19.57price
$47.45mean
$59

Sell if holding. Engine safety override at $19.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 3.26; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Score 5.3/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, earnings proximity 103d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 13, 2026

Recent Developments — Tyra Biosciences, Inc.

Latest item Nov 13, 2026 · Generated 2026-11-18T11:57:28Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Mar 2, 2027103d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: oral dabogratinib
Concentration risk — Supplier: third parties
Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.6
Mkt Cap$1.4B
EV/EBITDA-3.6
Profit Mgn0.0%
ROE-34.9%
Rev Growth—
Beta0.67
DividendNone
Analysts with ratings21

Quality Signals

Piotroski F4/9

Options Flow

P/C3.26bearish

Concentration Risks(10-K Item 1A)

  • HIGHpipelineoral dabogratinib
    10-K Item 1: 'Our lead program, oral dabogratinib, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects'
  • HIGHSupplierthird parties
    10-K Item 1A: 'We rely on third parties for the manufacture of our product candidates for preclinical and clinical development.'

Material Events(8-K, last 90d)

  • 2026-04-17Item 5.02LOW
    Tyra Biosciences board increased authorized directors from nine to ten and appointed Habib J. Dable as Class II director, term expiring at 2026 annual meeting. Dable is an advisor at RA Capital Management and former CEO of Acceleron Pharma.
    SEC filing →
  • 2026-04-02Item 5.02LOW
    Julia Rueb, VP Finance, designated as principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman in that specific role. Fuhrman continues as principal financial officer. No CFO departure.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Macd
1.9
Rsi
3.5
Volume
4.0
Volume distribution (falling OBV)Below 200-MA, MA slope -3.9%/30d — confirmed downtrend

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
News Activity
6.0
Earnings concerns: 0B/4M
GatesMomentum 2.3<4.5Death cross (50MA < 200MA)Executive change: officer departure/appointmentA.R:R 9.2 ≥ 1.5Insider activity: OKEARNINGS PROXIMITY 103d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
33 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $19.27Resistance $23.00

Price Targets

$19
$41
A.Upside+111.0%
A.R:R9.2:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (1.6 < 4.0)
! momentum at 2.3 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

M
M
M
M
0/4 beats
Next Earnings2027-03-02 (103d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TYRA stock a buy right now?

Sell if holding. Engine safety override at $19.57: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 9.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 3.26; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Prior stop was $18.69. Score 5.3/10, moderate confidence.

What is the TYRA stock price target?

Analyst target: $41.29 (+111.0% upside). Prior stop was $18.69. Stop-loss: $18.69.

What are the risks of investing in TYRA?

Concentration risk — Pipeline: oral dabogratinib; Concentration risk — Supplier: third parties; Quality below floor (1.6 < 4.0).

Is TYRA overvalued or undervalued?

Tyra Biosciences, Inc. trades at a P/E of N/A (forward -6.6). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about TYRA?

21 analysts rate TYRA, with a consensus score of 4.3/5. 11 analysts publish price targets averaging $47.

What does Tyra Biosciences, Inc. do?Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or...

Tyra Biosciences is a clinical-stage biotech developing FGFR-targeted precision medicines, with no approved products or commercial revenue. The lead program, oral dabogratinib, is advancing through three concurrent Phase 2 trials in LG-UTUC, IR NMIBC, and achondroplasia in children. The company reported net losses of $119.9 million in 2025 and has cash expected to fund operations through at least 2027.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · HALO (Halozyme Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · MGTX (MeiraGTx Holdings plc) · BMRN (BioMarin Pharmaceutical Inc.)
Home › Stocks › TYRA

Latest news

Latest News

Fiscal.ai5d ago
Fiscal.ai6d agoAnalyst
Benzinga7d ago
Benzinga7d agoAnalyst
Fiscal.ai8d ago
Benzinga8d ago
Fiscal.ai13d ago
Fiscal.ai13d agoEarnings
Benzinga27d ago
Benzinga57d ago
Benzinga64d ago
Benzinga64d ago
Benzinga65d ago
Benzinga65d ago
Benzinga69d agoAnalyst
Benzinga70d ago
Benzinga70d ago
Benzinga70d ago
Benzinga70d agoProduct
Benzinga75d agoAnalyst
Loading more...